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1. Introduction 
T1D is a tissue specific and T cell–mediated autoimmune disease characterized by the 
inflammation of pancreatic islets, namely insulitis, resulting in selective destruction of 
insulin-producing beta islet cells and development of overt diabetes (Atkinson & Leiter, 
1999, Bach, 1994, Mathis et al., 2001, McDevitt, 2001, Nepom & Kwok, 1998, Quinn et al., 
2001). The onset of T1D is preceded by at least two main inflammatory stages during 
insulitis development (Bach, 1994, Robles et al., 2003). In the first stage, termed peri-insulitis, 
a mixed population of leukocytes, including macrophages, dendritic cells, and T cells, 
migrate from draining lymph nodes to the peripheral space to the islets. In the second stage, 
the leukocytes further migrate and infiltrate into the islets, resulting in invasive insulitis. 
Overt T1D will develop when the majority of insulin-producing  cells in the islets are 
destroyed by the invading leukocytes and insufficient insulin is produced to control blood 
glucose levels in the body. Among leukocytes that infiltrate the islets, the autoantigen-
specific diabetogenic T cells play a critical role in development of T1D. Recruitment or 
homing of these diabetogenic T cells into the islets is a critical component of insulitis leading 
to T1D.  Thus inhibition of their homing to the islets would prevent the development of 
insulitis and T1D.  Consequently, it is necessary to understand the homing or trafficking 
behavior of diabetogenic T cells during the formation of peri-insulitis and invasive insulitis. 
The knowledge gained from studies addressing those questions is imperative to the 
development of early diagnosis methods and immune modulatory approaches to treat T1D.  
Due to the low number and frequency of T cells specific for an autoantigenic peptide, it has 
been difficult to identify and trace autoantigen-specific T cells in animals. We have 
previously addressed this problem by generating novel MHC class II tetramers that can 
stain T cells specific for a self peptide recognized presented by the MHC class II molecules 
such as the I-Ag7 in NOD mice (Liu et al., 2000, Chen et al., 2003, You et al., 2003). Using this 
approach, we have been able to successfully identify and trace autoantigen-specific T cells, 
such as the CD4+ BDC2.5 (BDC) T cells. The tissue localization of various T cell populations 
at any given time point can be identified using techniques such as flow cytometry and 
immunofluorescence. However, these methods involve an invasive approach requiring 
tissue removal from animals, and therefore only provide terminal data. As such, these 
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methods cannot help us assess real-time dynamic cell migration patterns in vivo as a 
longitudinal study. Therefore, it is desirable to address the above-mentioned questions 
using non-invasive in vivo imaging approaches. 
Previous studies have shown that it is possible to monitor T cells and other immune cells in 
deep organs in small animals (Weissleder, 1999). In particular, positron-emission 
tomography imaging (PET) of radio-labeled cells (Oku et al., 1994, Koike et al., 1997, 
Kikkawa et al., 2000, Melder et al., 2002, Adonai et al., 2002) and magnetic resonance 
imaging (MRI) of probe-labeled cells (Lewin et al., 2000, Dodd et al., 2001, Moore et al., 2002) 
have been used to image cell trafficking in small animals. In addition, in vivo imaging of 
pancreatic infiltration of CD8+ T cells labeled with nanoparticles using MRI (Moore et al., 
2004) has been demonstrated. These techniques offer high resolution images. However, the 
intensity of the probes or radio-isotopes used for labeling cells is rapidly decreased over 
time. This is inappropriate for in vivo imaging that requires long-term monitoring and 
evaluation of T cell trafficking in various animal tissues. Therefore, the need for a non-
invasive longitudinal imaging method for use in living animals is especially relevant to 
studies on a chronic autoimmune disease like T1D. Such methods may be used to reveal the 
T cell in vivo behavior, the kinetics of their appearance, and their persistence in various 
tissues over the course of the disease and in response to therapy. Using whole body in vivo 
imaging, one can develop imaging-guided assays that help investigators to determine the 
timing for tissue sampling, and ex vivo assays for functional and pathological assays.  
Whole body in vivo imaging assays help investigators assess whether novel T1D treatments 
may be effective in preventing or intervening T1D by modulating T cell trafficking in living 
animals. Therefore, other than PET and MRI, alternative imaging approaches need to be 
developed to better understand the trafficking behavior of diabetogenic T cells in pre-
clinical animal studies and to evaluate the effects of various diabetes treatment regimens on 
the trafficking of these T cells.   
Over the past decade, new imaging technologies for monitoring molecular and cellular 
changes in living animals have been developed. These methods were developed to help 
reveal the in vivo migratory behavior and/or paths of vitally important lymphocytes in 
response to altered immune conditions. In particular, bioluminescence imaging (BLI) 
technology has been a promising noninvasive imaging method that can be employed not 
only to image lymphocyte migration in vivo but also longitudinally monitor their behavior 
under various disease conditions (Hardy et al., 2001, Costa et al., 2001, Bhaumik and 
Gambhir, 2002, Scheffold et al., 2002, Edinger et al., 2003). These unique features are 
important for studies that need to investigate the in vivo roles of lymphocytes in chronic 
autoimmune diseases such as T1D. In our studies, we have used BLI to longitudinally 
monitor T cell trafficking in real time in living animals. To understand the in vivo behavior 
and tissue localization of T cells involved in T1D, we have established the experimental 
condition in which the trafficking of autoantigen-specific diabetogenic T cells in living 
animals can be successfully visualized using BLI. More importantly, aided by using the BLI 
approach, we have been able to examine the in vivo roles of nTreg cells on autoantigen-
specific diabetogenic T cells during the pathogenesis of T1D. These studies also have helped 
us to uncover the tissue localization and potential site of action of nTreg cells during the 
induction of immune tolerance that prevents T1D development.   
In the following sections, we will review some of the results obtained from in vivo BLI 
analyses of dynamic trafficking patterns of luciferase-expressing diabetogenic T cells under 
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various disease conditions. We will focus our discussion on the findings from studies that 
have examined the in vivo behavior of autoantigen-specific diabetogenic T cells in pre-
diabetic and newly diabetic animals, under conditions that either have or have no nTreg 
cells present in animals. We will also review the effect of nTreg cells on trafficking of 
pathogenic T cells in vivo, and the potential role and site of action of nTreg cells during the 
development of T cell-mediated insulitis leading to T1D.  
2. In vivo imaging of pathogenic T cell-mediated insulitis during development 
of overt type 1 diabetes 
In vivo tracking of autoreactive lymphocytes in intact micro-environment and macro-
environment in vivo in real time has been a long sought-after goal of investigators who are 
developing imaging techniques in the context of autoimmunity. T1D is an organ-specific 
autoimmune disease in which both autoreactive CD4+ and CD8+ T cells participate in the 
destruction of pancreatic insulin-producing islet  cells. Development of clinical symptoms 
of overt diabetes is preceded by a prolonged period of chronic inflammation in the islets. 
This is characterized by mononuclear cell infiltration of the islets that involves the 
recruitment and differentiation of autoreactive T cells (Liblau et al., 2002). A study aiming at 
understanding the role of CD8+ T cells in T1D has demonstrated pancreatic infiltration of 
CD8+ T cells using MRI by labeling the T cells with nanoparticles (Moore et al., 2004). In 
addition, the small animal imaging systems using PET or MRI have made it possible to 
monitor not only T cells but also other immune cells in deep organs in rodents (Weissleder, 
1999, Oku et al., 1994, Koike et al., 1997, Kikkawa et al., 2000, Melder et al., 2002, Adonai et 
al., 2002). Although considered as sensitive techniques, these approaches are not 
appropriate for a longitudinal study of chronic diseases such as T1D. In addition, although 
intravital microscopy provides greater spatial resolution than the other imaging approaches 
(Jain et al., 2002), this method involves invasive procedures. In order to better image 
ongoing immune response and T cell trafficking in living animals, several noninvasive 
imaging techniques have been employed to monitor leukocytes in various disease 
conditions using animal models (Moore et al., 2004, Denis et al., 2004, Hardy et al., 2001, 
Contag et al., 1998).  
Despite extensive studies on the role of T cells in T1D, their in vivo behavior, trafficking 
pattern and tissue localization over the course of chronic insulitis development leading to 
T1D remain unclear.  In order to address these important questions, we have performed 
longitudinal studies using in vivo BLI analyses in real time to noninvasively visualize 
autoantigen-specific diabetogenic T cell trafficking in mice under normal and diseased 
conditions. These studies were performed prior to and after the development of insulitis and 
overt diabetes in animal models. This approach of using BLI to image T cell trafficking offers 
the advantages of excellent temporal analyses, cell-labeling versatility, easily accessible 
instrumentation, and high sensitivity of signal detection (Cao et al., 2005, Cao et al., 2004, 
Wetterwald et al., 2002, Hardy et al., 2001, Contag et al., 1998). It is well known that the 
trafficking of diabetogenic CD4+ T cells such as BDC cells to the pancreas is necessary in 
order to induce insulitis and cause diabetes. Diabetogenic CD4+ T cells can also facilitate the 
homing of CD8+ T effector cells to the islets during insulitis and diabetes development 
(Thivolet et al., 1991). Therefore, these T cells play an important role during T1D 
development. However, the longitudinal trafficking behavior of diabetogenic CD4+ T cells to 
the pancreas during islet inflammation and diabetes development still remains largely 
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unclear. Although we have been able to trace T cells such as BDC cells using antigen-specific 
tetramers (Liu et al., 2000, You et al., 2003), these methods are invasive, requiring tissue 
removal from animals; hence, only terminal data can be obtained. The data obtained from 
non-invasive imaging analyses can help guide investigators in making decisions on tissue 
sampling for the invasive assays. Whole-body in vivo imaging such as BLI will help the 
investigators perform longitudinal studies that examine the in vivo behavior of diabetogenic 
T cells. Additionally, they will be able to assess whether treatments to prevent diabetes or 
islet graft rejection can be mediated through modulating the systemic trafficking T cells in 
living animals, in addition to other cellular functions. 
2.1 Real time bioluminescent imaging analyses  
Previous studies have shown that BLI analyses can be used to view cell trafficking in small 
animals, using luciferase (Luc) as an in vivo reporter (Hardy et al., 2001, Costa et al., 2001, 
Bhaumik and Gambhir, 2002, Scheffold et al., 2002, Edinger et al., 2003). Luciferase  provides 
excellent signal to noise ratios owing to the fact that there is almost no background 
luminescence from mammalian tissues. The photons emitted from Luc-expressing cells that 
are transmitted through tissues can be detected using charge-coupled device (CCD) cameras 
designed for lowlight imaging. BLI allows for long-term longitudinal studies of cell-
trafficking patterns because the reporter is encoded in the genome of the cells and the signal 
is therefore replicated during cell division, and is not diluted (Nakajima et al., 2001, Costa et 
al., 2001). BLI modalities that use light-generating enzymes (e.g. luciferase) and low-light 
imaging devices based on exquisitely sensitive CCD cameras have been developed and 
refined during the past decade. This system is capable of noninvasively revealing the 
cellular and molecular features of normal and diseased conditions in vivo. This approach 
offers the advantages of excellent temporal analyses, cell-labeling versatility, easily 
accessible instrumentation, and high sensitivity of signal detection (Contag et al., 1998, 
Hardy et al., 2001, Cao et al., 2005, Cao et al., 2004, Wetterwald et al., 2002).  This approach 
has also been proven to be very useful for longitudinally monitoring the in vivo behavior of 
the lymphocytes that cause chronic inflammation prior to development of autoimmune or 
inflammatory diseases. 
2.2 Noninvasive real-time in vivo bioluminescence imaging of diabetogenic T cell 
trafficking patterns 
The CD4+ BDC2.5 (BDC) cells are islet antigen–specific and highly diabetogenic T cells 
(Haskins and McDuffie, 1990, Haskins et al., 1989). Activated BDC cells from BDC TCR 
transgenic NOD mice (BDC mice) induce an aggressive form of diabetes (Chen et al., 2006, 
Katz et al., 1995). To label T cells from these animals for trafficking studies, we crossed a 
transgenic reporter mouse line that expresses luciferase by a strong, ubiquitous, constitutive 
promoter with BDC mice for more than 8 generations (luc-BDC/NOD mice) (Cao et al., 
2004). This synthetic hybrid promoter is composed of the chicken -actin promoter and the 
immediate early enhancer from cytomegalovirus, and thus drives expression of Luc into 
virtually all cells in the mice (Cao et al., 2004). Therefore, transgenic expression of the Luc 
transgene in BDC mice results in stable expression of Luc in all BDC cells. Using these Luc-
expressing BDC/NOD mice allows for long-term longitudinal in vivo imaging studies of 
Luc+ BDC cell trafficking to the pancreas and the islets, as well as other lymphoid and 
nonlymphoid tissues relative to varied degrees of disease states in animals.  
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It is known that transferring CD4+ BDC cells alone into NOD/scid mice failed to induce 
diabetes. However, cotransfer of CD4+ cell–depleted splenocytes isolated from diabetic 
NOD mice with CD4+ BDC cells induced accelerated diabetes in recipient mice.  It has also 
been observed that there can be a respectful degree of peri-insulitis or invasive insulitis 
(Katz et al., 1995, Katz et al., 1993, Peterson & Haskins, 1996). However, the mechanisms 
responsible for these novel observations were not clear. At least two non-mutually exclusive 
possibilities exist that may explain the effect of the non-CD4 splenocytes on CD4+ BDC cells 
during induction of expedited diabetes: (1) The non-CD4 splenocytes may cause an altered 
systemic trafficking pattern of BDC cells that prevents their homing to the islets, or (2) they 
may exert their effect on BDC cells locally at tissue levels. We have addressed these 
questions in our studies which will be discussed in more detail below. 
 
 
Fig. 1. Real-time in vivo bioluminescence imaging of luciferase-expressing primary CD4+ 
BDC cells. The CD4+ T cells were isolated from luc-BDC/NOD mice and i.v.  injected into 9-
wk old female NOD/scid mice (10x106 cells / mouse). The images were taken at different 
time points after cell transfer by a CCD camera. SPL: spleen, ILN: inguinal lymph nodes, 
PAN; pancreas. 
We imaged BDC cells in vivo using BLI and compared their trafficking patterns in 
nondiabetic mice that received BDC cells alone with the trafficking patterns in prediabetic 
and newly diabetic recipients that were cotransferred with BDC cells plus CD4- splenocytes 
isolated from diabetic NOD mice. We also used these data to determine the best timing and 
the target tissues for further analyses using methods that would enable us to assess the 
effects of CD4+ cell–depleted splenocytes on the local patterns of BDC cells.  
Using an adoptive transfer model, we have imaged Luc+ CD4+ BDC cells and examined their 
trafficking patterns in real time in NOD/scid mice recipients (Fig. 1). In order to monitor 
diabetogenic T cell trafficking patterns in real-time in vivo using noninvasive BLI, we first 
isolated CD4+ Luc+ BDC cells from Luc-BDC/NOD mice and adoptively transferred them 
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into NOD/scid recipient mice for BLI analyses. Using this approach, we were able to 
visualize just the BDC cells that expressed luciferase. To perform longitudinal studies on the 
trafficking behavior of the CD4+ BDC cells in recipient mice, the same living recipient mice 
were imaged at selected times over a period of 16 weeks following cell transfer.  Initial 
signals from the transferred Luc+ BDC cells in recipient mice were detected in their lungs on 
the first day after transfer. The BLI signals were then detected in other organs including the 
pancreas and the liver by day 3 (data not shown). We have also detected the BLI signals 
from Luc+ BDC cells in lymphoid organs such as the spleen and lymph nodes within 1 week 
after the cell transfer (Fig. 1).  
To quantify the bioluminescent signals detected from various tissues in the recipient mice, 
the total flux (photons/sec) was determined by drawing regions of interest (ROI) over the 
body corresponding to the designated organs. Based on these results, we have determined 
the total photon output per ROI to calculate the bioluminescence signal intensity. Each ROI 
was visually defined to be specific areas that correspond to selected organs from both 
recipient animals and control mice. The rates of increase in the in vivo bioluminescence 
signals detected in the ROI corresponding to the pancreas, spleen, and inguinal lymph 
nodes closely correlated with each other. These results indicate that the transferred BDC 
cells eventually accumulated and may also have proliferated in these tissues at the later time 
points, perhaps due to homeostatic expansion (Lee et al., 2007). Owing to the relatively low 
level of photon flux (photon/sec), especially in the pancreas at early time points, different 
colored bar scales were used for day 1 through day 15 (2,000–50,000) and for day 20 through 
day 113 (5,000–50,000). The data shown are from a representative mouse from at least 20 
mice of four different experiments. The total photon flux was greatest in the spleen and 
lungs; the pancreas and mesenteric lymph nodes also showed significantly higher photon 
flux than the other tissues analyzed. The BLI signals from control mice were negligible. 
Quantification of luciferase activity in the dissected tissues is subject to oxygen availability 
in addition to levels of substrate and adenosine triphosphate. As such, it may not constitute 
a highly quantitative measurement. Additionally, although we cannot directly compare 
these in vivo BLI signals among different tissues without normalizing the tissue volume, we 
have also performed ex vivo BLI analyses by excising the tissues from the mice for BLI. The 
results from ex vivo BLI analyses on each tissue were confirmed by using the more 
quantitative FACS analyses by staining the BDC cells with BDC cell-specific I-Ag7-
tetramers. 
In summary, these noninvasive in vivo imaging studies revealed that, although BDC cells 
migrated to the pancreas rapidly after cell transfer, and the BLI signals of BDC cells detected 
in the pancreas ROI increased significantly with time, the recipient mice did not develop 
diabetes. Other than revealing in real time the rapid appearance of a large number of BDC 
cells in the pancreas without causing diabetes, these imaging results are also consistent with 
the idea that islet-antigen-specific diabetogenic T cells are able to traffic to the pancreas 
regardless of whether they induce diabetes. Therefore, these results support the notion that 
the recruitment and accumulation alone of a large number of diabetogenic T cells, like the 
BDC cells, are insufficient to induce overt diabetes. 
2.3 Real time bioluminescent imaging of diabetogenic T cells during the development 
of insulitis leading to diabetes 
The fact that a large number of Luc+ CD4+ BDC cells present in the islets did not induce 
diabetes in the recipient mice was not due to the introduction of luciferase transgene into 
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BDC mice. This is because purified Luc- CD4+ BDC cells obtained from BDC mice of the 
same age in our mouse colony also did not induce diabetes in recipient mice (unpublished 
data). One possible explanation of these results is that the BLI analyses study was 
terminated before overt diabetes developed; however, the control mice receiving whole BDC 
mouse splenocytes develop diabetes within 6 weeks after cell transfer (Chen et al., 2006). 
This explanation seems unlikely because our additional studies have shown that recipient 
mice did not develop diabetes even at 23 weeks following the transfer of BDC cells alone 
(unpublished data). Alternatively, it is possible that BDC cells require the presence of other 
types of cells in the spleen in order to destroy the islets and induce diabetes.  
It has been shown that transfer of T cells alone did not induce diabetes, and the presence of 
non-CD4+ cells such as CD8+ T cells are necessary (Bendelac et al., 1987, Christianson et al., 
1993, Miller et al., 1988). Previous studies have also shown that cotransfer of the CD4+ BDC 
cells with CD4+ cell–depleted splenocytes from newly diabetic NOD mice induced accelerated 
diabetes in the recipient animals (Peterson and Haskins, 1996). In order to understand the 
trafficking behavior of BDC cells during islet inflammation that leads to diabetes, we co-
transferred purified CD4+ Luc+ BDC cells and CD4+ cell–depleted Luc- splenocytes from newly 
diabetic NOD mice into NOD/scid recipient mice. Our results showed that the recipient mice 
receiving non-CD4+ splenocytes alone did not develop diabetes. However, the mice that 
received both populations of cells developed diabetes as early as 9 days following cell transfer, 
and all recipient mice developed accelerated diabetes within 3 weeks.  
In order to understand the behavior of BDC cells in these mice, BLI studies showed that the 
kinetics of Luc+ BDC cells’ trafficking in mice that were cotransferred with both CD4+ Luc+ 
BDC cells and CD4+ cell–depleted Luc- splenocytes from newly diabetic NOD mice were 
similar, at the level of the whole body and organs, to the kinetics in recipient mice that have 
BDC cells alone. In both types of recipients, the BDC cells migrated first to the lung in one 
day and then to the pancreas, inguinal lymph nodes, and spleen within one week. To further 
quantify and compare the changes in BLI signal intensity (total flux) in various tissues of the 
two different groups of recipient mice at the same time points, we imaged BDC cells and 
analyzed the ROI drawn on various tissues including the pancreas. The ROI analyses 
showed that the total BLI signal intensity gradually increased over time. A similar trend of 
signal intensity increase was also detected in the pancreas ROI in both cohorts, although the 
transferred Luc+ BDC cells continued proliferating in the lymph organs in mice that received 
both cell types. Comparable levels of BLI intensity over time were detected in the lymphoid 
organs in both groups of mice before all the mice that received both types of cells became 
diabetic following a cotransfer of the cells. However, the BLI intensity in lymphoid organs 
increased at a faster rate in co-transferred mice during the post-diabetic period than that 
detected in nondiabetic mice that received BDC cells alone. Therefore, cotransfer of CD4- 
splenocytes led to diabetes but did not otherwise change the overall trafficking patterns of 
BDC cells to these tissues during the pre-diabetic stage. These results suggest that the co-
transferred splenocytes may not help BDC cells to induce accelerated diabetes by 
modulating the trafficking and the total number of BDC cells in the pancreas. Instead, they 
may cause an increased proliferation of BDC cells in tissues other than the pancreas. BDC 
cells were able to induce insulitis in both groups of recipients, but only the co-transferred 
recipients developed diabetes. Therefore, it is likely that the total number of BDC cells 
present in the pancreas is not responsible for the development of diabetes. It may be that the 
cellular function of immune cells present within the islets and the microscopic localization 
of the cells within the tissue were the contributors  to diabetes development in our studies.  
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Different degrees and types of insulitis may occur in the recipient animals after transfer of 
varied cell populations. Peri-insulitis does not lead to islet destruction, whereas invasive 
insulitis destroys islets and leads to diabetes. To further evaluate why the cotransferred 
CD4- splenocytes may help BDC cells induce accelerated diabetes, we examined whether 
these splenocytes promote infiltration of BDC cells into the islets and induce invasive 
insulitis. To make these distinctions, we performed microscopic imaging of the islets 
(since there is no macroscopic imaging method able to distinguish cell distribution 
differences at this resolution). Initial ex vivo BLI analyses of excised pancreases showed 
that comparable bioluminescent signals were detected in the pancreas of both groups of 
recipients (Lee et al., 2007). These results demonstrated that BDC cells can traffic to the 
pancreas independent on the presence of other splenocytes. Additonal histological 
analyses showed that mice co-transferred with both cell types developed more severe 
invasive insulitis than mice that received BDC cells alone. The islets in the pancreatic 
sections obtained from co-transferred mice on day 20 following cell transfer showed 
invasive insulitis and were severely damaged. Only peri-insulitis were detected in the 
islets from mice transferred with BDC cells alone and their islets remained intact. 
Therefore, the co-transferred splenocytes may help induce diabetes by enhancing the local 
infiltration of BDC cells into the islets.  
We also performed FACS analyses to better understand the cellular component of the 
invasive insulitis found in the co-transferred mice. We found that the percentage of both 
CD11b+ cells and CD11c+ cells showed increase only in the islets of co-transferred mice 
(Lee et al., 2007). These results suggest that these innate immune cells are involved in 
promoting invasiveness of BDC cells into the islets. One possibility is that these cells help 
activation of BDC cells, leading to more activated BDC cells in the islets of co-transferred 
mice and resulting in accelerated diabetes. Investigation on the activation status of BDC 
cell present in the islets show that there was no difference in expression of activation 
markers, CD69 and CD62L, on BDC cells isolated from the islets of both cohorts. Overall, 
our results suggest that efficient trafficking of BDC cells alone to the pancreas is unable to 
induce T1D alone. The presence of CD4- splenocytes is necessary to help these pathogenic 
T cells locally infiltrate the islets without altering their activation status and systemic 
trafficking patterns.  
In summary, these findings are possible  because investigators have the ability to image T 
cell trafficking and tissue localization over a range of varied scales of techniques, from 
macroscopic imaging and whole-body BLI, to microscopic imaging via light microscopy of 
tissue sections and single cell analyses using FACS. 
2.4 Application of BLI to understand the role of nTreg cells in regulating the in vivo 
behavior of diabetogenic T cells during T1D 
The naturally-arised Foxp3+ CD4+ CD25+ nTreg cells play a critical role in immune tolerance 
induction and autoimmune disease prevention (Sakaguchi and Powrie, 2007). It is well 
known that a deficiency in nTreg cells may contribute to development of insulitis and T1D 
in both humans and mice. Rebuilding a sufficient number of nTreg cells can re-induce 
immune tolerance, leading to inhibition of T1D (Herman et al., 2004, Tang et al., 2004, 
Tarbell et al., 2004, Brusko et al., 2005, Lindley et al., 2005, Tritt et al., 2008). Extensive 
studies have been performed to understand the role of nTreg cells during T1D. However, it 
is still largely unclear as to how these potent nTreg cells prevent destruction of the insulin-
producing beta islet cells by pathogenic T cell-mediated immune responses. 
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As discussed in previous sections, the development of insulitis precedes development of 
overt T1D, and immune tolerance induced by nTreg cells often leads to prevention of 
insulitis in diabetes-free mice. It is conceivable that the development of insulitis involves at 
least four stages as outlined and depicted in Figure. 2. These include: (1) migration of 
antigen-presenting cells (APCs), such as macrophages and dendritic cells, to islet draining 
lymph nodes where the APCs can pick up islet antigens and present them to T cells; this 
leads to activation of autoreactive pathogenic T cells such as BDC cells in the lymph nodes, 
(2) expansion of activated pathogenic T cells, (3) migration of activated pathogenic T cells to 
the islets, and (4) infiltration of the pathogenic T cells into the islets, causing invasive 
insulitis and destruction of the islets.  It is possible that in order to inhibit insulitis and T1D, 
nTreg cells may function by blocking pathogenic T cells at one of these four stages. For 
example, nTreg cells may modulate systemic trafficking behavior of pathogenic T effector 
cells such as BDC cells as well as APCs during the pre-diabetic stage. In addition to 
suppressing pathogenic T effector cell proliferation and expansion, nTreg cells may block 
 
 
Fig. 2. Potential roles of nTreg cells in controlling T1D pathogenesis. Beta cell antigens are 
released from the islets into the circulation system. The islet antigens are taken up by the 
antigen presenting cells (APCs) that have migrated from the circulation to pancreatic 
draining lymph nodes. In the draining lymph nodes, islet antigen-specific pathogenic T 
effector cells are activated by islet antigen-loaded APCs, leading to expansion of pathogenic 
T cells. The expanded pathogenic T cells then traffic to the islets and induce insulitis. 
Another causative factor in insulitis development is the recruitment of innate immune cells 
such as macrophages and dendritic cells. This process eventually leads to destruction of islet 
beta cells and onset of overt diabetes. It is hypothesized that nTreg cells may prevent 
insulitis and T1D development at one of the four indicated stages. 
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the trafficking and homing of such T cells to the islets, resulting in inhibition of invasive 
insulitis that causes overt T1D. It is also possible that, in the absence of nTreg cells, the 
pathogenic T cells such as BDC cells may traffic more rapidly to and accumulate faster in the 
islets during pre-diabetic stage. This eventually leads to destruction of the insulin-producing 
islet beta cells and onset of diabetes.  
In our studies to test these different hypotheses, we have performed several experiments, 
including real time imaging studies, to investigate whether BDC cells showed an altered 
trafficking pattern in nTreg cell-deficient mice compared to that in nTreg cell-sufficient mice. 
In order to examine the role of nTreg cells in vivo in T1D and distinguish their effects on T1D 
onset during the four stages of insulitis development, we have used the novel animal 
models described in the previous sections for imaging analyses. In these studies, as part of 
our approaches, we have performed noninvasive BLI-guided in vivo analyses of BDC cell 
trafficking in real-time under varied conditions in the presence or absence of nTreg cells 
(Lee et al., 2010). In particular, in these studies we performed experiments to address the 
following questions: (1) Compared to nTreg cell-deficient mice, can the trafficking and 
systemic tissue localization of BDC cells be modulated by nTreg cells during development of 
T1D? (2) Does the presence of nTreg cells affect the in vivo priming, activation, and 
expansion of BDC cells during the development of T1D? and (3) How does nTreg cells 
modulate BDC cell-mediated invasive insulitis during T1D? 
As part of our studies to address these questions, we used a cell adoptive transfer model by 
transferring CD4+ BDC cells into NOD/scid recipient mice.  It is known that the transfer of 
CD4+ CD25- (nTreg-deficient) BDC cells into NOD/scid mice induces aggressive T1D, 
whereas the transfer of CD4+ (nTreg cell-sufficient) BDC cells does not cause onset of T1D in 
recipient mice. Therefore, to longitudinally monitor trafficking of the adoptively transferred 
BDC cells in mice with or without nTreg cells, we have isolated Luc+ CD4+ CD25- (nTreg-
deficient) or Luc+ CD4+ (nTreg cell-sufficient) BDC cells from Luc-BDC/NOD mice. We then 
adoptively transferred these cells separately into NOD/scid recipient mice. Trafficking and 
tissue localization of the transferred Luc+ BDC cells in the two cohorts were monitored until 
after the recipient mice that received Luc+ CD4+ CD25- (nTreg-deficient) BDC cells 
developed T1D (Lee et al., 2010).  
We have performed initial macro imaging analyses using BLI on recipient mice during the 
pre-diabetic stages. Our in vivo BLI analyses results showed that, during the pre-diabetic 
stage on and before the fifth day after cell transfer, there was no significant difference in  
bioluminescence signal noted in any of the tissues examined between the two cohorts. 
These results suggest that the presence or absence of nTreg cells may not significantly 
affect the trafficking of BDC cells prior to development of T1D. On the other hand, an 
increased BLI signal was detected in several tissues in nTreg cell-deficient, but not control 
nTreg cell-sufficient mice, only at the postdiabetic stage after development of T1D on or 
after day 7. The reasons for this difference were unclear, but it could have been a result of 
a more rapid local expansion of BDC cells that migrated to and resided in these tissues in 
the absence of nTreg cells. These results demonstrated comparable trafficking and tissue 
localization of BDC cells during the prediabetic stage in both cohorts of mice. The imaging 
study results also suggest that nTreg cells may not prevent T1D by modulating the 
systemic trafficking behavior of pathogenic T cells or the expansion of such cells during 
the pre-diabetic stages. 
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Fig. 3. The nTreg cells may prevent inulitis and T1D by functioning locally in the islets. They 
may negatively affect not only pathogenic T cells but also innate immune cells recruited to 
the islets. 
In addition to macro imaging studies on systemic in vivo trafficking of T cells, we also 
determined whether nTreg cells may prevent T1D by modulating inflammatory processes 
locally in the islets. In particular, we performed micro imaging analyses and histological 
analyses of the islets. These studies showed that depletion of nTreg cells promoted 
progression and increased severity of insulitis in nTreg cell-deficient mice. Therefore, nTreg 
cell-deficient mice developed more severe invasive insulitis, compared to mostly peri-
insulitis found in control nTreg cell-sufficient mice (Lee et al., 2010). However, despite these 
differences, the nTreg cell-deficiency did not affect the number and activation status of BDC 
cells during the pre-diabetic stage. These results suggested that cellular components other 
than or in addition to BDC T cells may be involved in the development from peri-insulitis to 
invasive insulitis leading to T1D.  It is possible that nTreg cells helped maintain the steady-
state of peri-insulitis in nTreg-sufficient mice. However, the steady-state of peri-insulitis in 
nTreg cell deficient mice may have been broken in the absence of nTreg cells. This in turn 
led to aggressive infiltration of immune cells from periphery space into the islets, resulting 
in invasive insulitis. Altogether, these results provide strong evidence supporting the notion 
that nTreg cells function locally in the islets.  
Based on the results discussed above, one can hypothesize that nTreg cells can exert their 
function by preventing the infiltration of immune cells from the periphery space into the 
islets. In the absence of nTreg cells, one would expect that the cellular components of 
invasive insulitis would be altered in comparison to those found in peri-insulitis that are 
maintained by the presence of nTreg cells. In addition, the change in cellular components in 
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the islets may be due to the nTreg cells’ ability to regulate the local migration of immune 
cells. In studies to address these questions, we found that, compared to that in control nTreg 
cell-sufficient mice, the accelerated invasive insulitis in nTreg cell-deficient recipient 
NOD/scid mice was predominated by a population of CD11c+ dendritic cells, instead of by 
the adoptively transferred CD4+ BDC T cells (Lee et al., 2010). These results suggest that the 
presence of nTreg cells may inhibit islet-infiltration of CD11c+ dendritic cells. Indeed, using 
an in vitro chemotaxis assay, we have found that the presence of nTreg cells were able to 
negatively regulate the chemotaxis of CD11c+ dendritic cells isolated from the islets in NOD 
mice. Therefore, these novel results suggest that nTreg cells may function locally in the islets 
by preventing invasive islet-infiltration of innate immune cells such as CD11c+ dendritic 
cells during development of overt T1D. In animals lacking nTreg cells, the deficiency may 
lead to enhanced islet infiltration of disease-promoting cells such as CD11c+ dendritic cells, 
perhaps due to an altered response to chemokines.  
In summary, using in vivo BLI-guided analyses, we have found that nTreg cells do not affect 
systemic localization of pathogenic T cells. Our results support the conclusion that nTreg 
cells can function locally in the islets to prevent inflammatory responses that cause invasive 
infiltration of innate immune cells, such as CD11c+ dendritic cells, into the islets. The nTreg 
cells may exert such function, at least in part, by regulating their chemotaxis in the islets. 
Altogether, our study demonstrated that dendritic cell-dominated invasive insulitis may 
precede T1D onset, and nTreg cells can prevent T1D by inhibiting local invasiveness of DCs, 
not CD4+ T cells, into the islets. 
3. Conclusions and therapeutic implications 
We have developed novel animal models that help investigators to perform in vivo BLI to 
visualize, in real time, the trafficking behavior of diabetogenic T cells in living animals 
under conditions that may or may not lead to diabetes. Based on the results obtained from 
these studies, we now have a better understanding of the kinetics, tissue localization, and 
relative cell numbers in various tissues in living animals during the development of islet 
inflammation and T1D. This approach is also used as an excellent initial assessment to 
understand the potential in vivo roles and site of action of nTreg cells during the 
development of T1D.  By combining the sensitive imaging studies through performance of 
BLI analyses with other approaches, our studies obtained from experiments on in vivo nTreg 
cell function in adoptive transfer animal models have helped us to uncover the structural 
and kinetic features associated with islet destruction and T1D pathogenesis in mice.  These 
results have demonstrated that non-invasive whole-body in vivo imaging-guided analyses, 
such as the use of BLI, is a useful and reliable tool for examining cell-trafficking patterns in 
animals during the onset of islet inflammation and diabetes. These methods are also useful 
for monitoring the potential outcomes or effects of various disease treatment regimens. For 
example, following treatment of chronic diseases like T1D, these approaches can help 
investigators to monitor the effects of the treatment on in vivo behavior of T cells in long-
term longitudinal studies.  
More importantly, these novel results demonstrate that, by combining micro and macro 
imaging analyses methods, the non-invasive in vivo imaging analyses can help guide the 
investigators to the times and tissues where the unique biology is taking place prior to and 
after development of inflammatory responses. These techniques will be a useful approach 
for monitoring the effects of various treatments that may regulate immune cell trafficking 
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and inhibit diabetes. In summary, in vivo imaging approaches can help elucidate the 
temporal patterns, spatial distribution, and site of action of various immune cells in the 
body during the development of T1D. In addition, based on the results obtained from these 
in vitro and longitudinal in vivo assays, it is possible to better understand the important roles 
of nTreg cells during the regulation of autoimmunity and restoring of self-tolerance in the 
treatment for autoimmune diseases like T1D. Cell-based immunotherapy, such as the ones 
involving nTreg cells, has provided promising hope for treating diseases such as T1D and 
graft-vs-host-diseases (Roncarolo and Battaglia, 2007). The information gained from the 
combination of various imaging approaches, including the ones described in this chapter, 
should aid in the design of Treg-based novel immune therapies to treat these life-
threatening diseases. 
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